Anlotinib Exerts Anti-Cancer Effects on KRAS-Mutated Lung Cancer Cell Through Suppressing the MEK/ERK Pathway

BACKGROUND: With a high frequency of 30%, KRAS mutations in patients with non-small cell lung cancer (NSCLC) often lead to their poor response to most anti-cancer therapies. As a multi-target tyrosine kinase inhibitor, Anlotinib shows clinical efficacy against several types of cancer. However, its e...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Haoyue, Liu, Yanyang, Tan, Songtao, Xie, Xiao Xiao, He, Jun, Luo, Feng, Wang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250708/
https://www.ncbi.nlm.nih.gov/pubmed/32547195
http://dx.doi.org/10.2147/CMAR.S243660

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250708/
https://www.ncbi.nlm.nih.gov/pubmed/32547195
http://dx.doi.org/10.2147/CMAR.S243660

Ejemplares similares